KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Working Capital Changes: 2010-2025

Historic Other Working Capital Changes for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $618,000.

  • Nektar Therapeutics' Other Working Capital Changes fell 82.73% to $618,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 205.06%. This contributed to the annual value of $4.2 million for FY2024, which is 216.86% up from last year.
  • Per Nektar Therapeutics' latest filing, its Other Working Capital Changes stood at $618,000 for Q3 2025, which was up 162.74% from -$985,000 recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Other Working Capital Changes ranged from a high of $10.8 million in Q3 2021 and a low of -$6.2 million during Q1 2021.
  • Over the past 3 years, Nektar Therapeutics' median Other Working Capital Changes value was $867,000 (recorded in 2023), while the average stood at $563,182.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first slumped by 160.15% in 2022, then soared by 510.45% in 2025.
  • Nektar Therapeutics' Other Working Capital Changes (Quarterly) stood at $3.4 million in 2021, then tumbled by 160.15% to -$2.0 million in 2022, then spiked by 142.40% to $867,000 in 2023, then spiked by 179.82% to $2.4 million in 2024, then crashed by 82.73% to $618,000 in 2025.
  • Its last three reported values are $618,000 in Q3 2025, -$985,000 for Q2 2025, and $6.0 million during Q1 2025.